| Name | Title | Contact Details |
|---|
Cedars-Sinai is a non-profit, academic, community-centric, Level 1 Trauma Center in Los Angeles, California. Recognized internationally, Cedars-Sinai brings together top healthcare professionals collaborating to provide exceptional patient care. A combination of patient satisfaction scores, clinical performance initiatives, excellent medical outcomes, national designations and awards and ongoing research and academic programs have earned Cedars-Sinai a top spot on the Honor Roll in the 2014-15 issue of America`s Best Hospitals by U.S. News and World Report. Out of nearly 5,000 hospitals surveyed for the annual rankings, Cedars-Sinai is among just 17 hospitals nationwide to earn the magazine’s Honor Roll designation. To be named to the Honor Roll, a hospital must be rated among the nation’s top 50 programs in at least six specialties. Cedars-Sinai was ranked in 12 categories, including: Cancer; Cardiology and Heart Surgery; Diabetes and Endocrinology; Ear, Nose and Throat; Gastroenterology and GI Surgery; Geriatrics; Gynecology; Nephrology, Neurology and Neurosurgery; Orthopedics; Pulmonology; and Urology. Cedars-Sinai has also received its fourth consecutive Magnet® recognition for nursing excellence from the American Nurses Credentialing Center (ANCC), becoming the hospital with the longest-running Magnet designation in California. Nationwide, only about 5% of hospitals have earned the four-year Magnet designation. Cedars-Sinai was the first Southern California hospital to earn the Magnet honor in 2000, and one of only six hospitals to receive this designation three times. Studies show that Magnet hospitals tend to have lower mortality and infection rates, as well as higher patient satisfaction and nurse staffing levels.
Kensington Retirement Comnty is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mobile Medical Intl is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Breastfeeding Support Consultants is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.